


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A therapeutical method comprising administration of an amount of oligo- β -(1,3)-glucan and a pharmaceutically acceptable carrier, to a human being or to a warm-blood animal suffering from a disease selected from the group consisting in a tumor, a cancer, a viral disease, a bacterial disease, a fungal disease, a disease of the immune system, an auto-immune disease or disease related to a deficiency of immunostimulation in an amount which is effective to treat the disease and, wherein the oligo- β -(1,3)-glucan is a compound presenting the following formula (1):



in which n=1 to 7,

or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Currently amended) The method according to claim 2 1, wherein the compound of claim 1 is Laminaritetraose (n=2) or Laminaripentaose (n=3).

4. (Original) The method of claim 1, wherein the cancer is breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestinal cancer or colon cancer.

5. (Original) The method according to claim 1, wherein the administration of oligo- β -(1,3)-glucan stimulates NK cells in the human being or warm-blood animal.

6. (Original) The method according to claim 1, wherein the administration of oligo- β -(1,3)-glucan stimulates the production of TNF-alpha in the human being or the warm-blood animal.


7. (Original) The method according to claim 1, wherein the composition is administered intravenously, intraperitoneally or orally to the patient.

8. (Original) The method of claim 1, further comprising administration of a chemotherapeutic agent.

9. (Original) The method of claim 1, further comprising administration of a potentiator.

10. (Original) The method according to claim 1, wherein the composition is under the form of a solution, suspension, syrup, tablet, capsule, injections, ointment, pulmonary, spray.

11. (Withdrawn) Pharmaceutical composition under the form of a solution, suspension, spray, aerosol, tablet, capsule, injection, ointment, pulmonary aerosol comprising a therapeutically effective amount of oligo-1-3- β glucan of formula (1)



in which $n=1$ to 7, preferably $n=2$ or $n=3$, or a salt pharmaceutically acceptable salt thereof, and a pharmaceutical acceptable carrier, said composition being free of any other glucan.